Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ORGANIZATION PhRMA Hails 2024 Reform, but Says Full Picture Unchanged as 50% of Patented Meds Still Face Cuts
April 4, 2024
-
REGULATORY Offset Technology-Driven Cost Rise with Spending Reforms: Govt Economic Estimate
April 3, 2024
-
ORGANIZATION Pharma Labor Group Makes Direct Plea to Lawmakers against Off-Year Price Cuts
April 3, 2024
-
REGULATORY Japan Health Minister Hints Positive Stance on Off-Year Price Revisions
April 3, 2024
-
REGULATORY Japan Govt Ends COVID Vaccine Supply as Emergency Program Winds Up
April 3, 2024
-
BUSINESS Sumitomo Offloads Entire Stake in Roivant as Earnings Tank
April 3, 2024
-
BUSINESS Daiichi’s TROP2 ADC Accepted for US FDA Review in Breast Cancer
April 3, 2024
-
REGULATORY Opposition Party Head Calls for Rethink of Public Health Coverage in Japan
April 3, 2024
-
COMMENTARY With Honebuto 2024 Looming, Now Is the Time to Revisit Social Security Spending
April 2, 2024
-
REGULATORY Japan Finalizes Generic Info Disclosure Guidelines for Company Indicator Rule
April 2, 2024
-
REGULATORY Japan Revises GMP Inspection Guide after Generic Manufacturing Issues
April 2, 2024
-
REGULATORY Japan’s Amended Next-Gen Medical Infrastructure Law Takes Effect
April 2, 2024
-
ORGANIZATION Wholesaler Group Launches Database for Unit Price-Based Negotiations
April 2, 2024
-
BUSINESS Axcelead-Teijin Drug Discovery Joint Venture Now Up and Running
April 2, 2024
-
BUSINESS MS Med Copaxone Transferred to Teva Takeda Pharma
April 2, 2024
-
BUSINESS Takeda to Hand Over Nihon Pharma to Alinamin in July
April 2, 2024
-
BUSINESS Cheplapharm to Take Over 5 Brands from Clinigen in Japan
April 2, 2024
-
BUSINESS Aculys Pharma Poaches Takeda Veteran as New CEO
April 2, 2024
-
BUSINESS New Ono Chief Eager to Go Solo in US, Europe; BTK Med 1st Shield against Opdivo Patent Cliff
April 1, 2024
-
REGULATORY Drug Makers in Japan Asked to Create Pediatric Development Plans from April
April 1, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…